|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Lucentis
|
|
gptkbp:activities
|
VEGF inhibition
|
|
gptkbp:appointed_by
|
injection
ophthalmology
intravitreal injection
|
|
gptkbp:approves
|
gptkb:legislation
gptkb:FDA
gptkb:United_States
|
|
gptkbp:clinical_trial
|
Phase III
choroidal neovascularization
wet age-related macular degeneration
|
|
gptkbp:developed_by
|
gptkb:Genentech
|
|
gptkbp:formulation
|
intravitreal injection
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ranibizumab
|
|
gptkbp:indication
|
gptkb:myopic_choroidal_neovascularization
retinal vein occlusion
diabetic macular edema
|
|
gptkbp:ingredients
|
C_6440_ H_10000_ N_2000_ O_2000_ S_1000
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_compared_to
|
gptkb:VEGF_Trap-Eye
|
|
gptkbp:is_used_for
|
treatment of age-related macular degeneration
treatment of diabetic macular edema
treatment of retinal vein occlusion
treatment of myopic choroidal neovascularization
|
|
gptkbp:marketed_as
|
gptkb:Lucentis
|
|
gptkbp:side_effect
|
retinal detachment
cataract
intraocular inflammation
|
|
gptkbp:targets
|
gptkb:vascular_endothelial_growth_factor_(VEGF)
|
|
gptkbp:weight
|
48.0 k Da
|